Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Capsaicin for Chemo-induced Peripheral Neuropathy
NCT06744816Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2025
- Primary completion
- Nov 2027
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of capsaicin 8% patch in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Changes in Gait velocity and Safety and adverse events. Started Dec 2025; status: recruiting.
02
Drugs
capsaicin 8% patch
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT06744816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06744816.